A randomized controlled trial of solcoseryl and duoderm in chronic sickle-cell ulcers.
A randomized controlled trial of Solcoseryl, DuoDerm and conventional conservative therapy with Eusol has been performed in 32 patients with homozygous sickle-cell (SS) disease. After 12 weeks' baseline observation, patients were randomized to one of three therapies and monitored for a further 12 weeks. Of 44 ulcerated legs, 20 received control treatment, 12 Solcoseryl and 12 DuoDerm. DuoDerm was generally unacceptable, and two-thirds of the patients defaulted from this treatment. Solcoseryl increased ulcer healing compared to the controls but the difference was not significant. Solcoseryl was well tolerated and may have a role in the treatment of chronic leg ulcers of sickle-cell disease.
La Grenade
L
L
Department of Medicine, U.W.I., Jamaica.
Thomas
P W
PW
Serjeant
G R
GR
D000183:Actihaemyl / Q000627:therapeutic use*; D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications*; D000890:Anti-Infective Agents / Q000627:therapeutic use; D047070:Bandages, Hydrocolloid; D001881:Borates / Q000627:therapeutic use; D002908:Chronic Disease; D003102:Colloids / Q000627:therapeutic use*; D006801:Humans; D007871:Leg Ulcer / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D009779:Occlusive Dressings; D012973:Sodium Hypochlorite / Q000627:therapeutic use
D000890:Anti-Infective Agents; D001881:Borates; D003102:Colloids; D000183:Actihaemyl; C024611:Eusol; D012973:Sodium Hypochlorite